Tuberculosis

Annals of Tropical Medicine and Parasitology

Volumn 100, Issue 5-6, 2006, Pages 415-431

  Harries, A D ^a,b,c   Dye, C ^d  

^a MINISTRY OF HEALTH   (Malawi)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ANTIRETROVIRUS AGENT; CAPREOMYCIN; COTRIMOXAZOLE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE TRANSMISSION; EXTRAPULMONARY TUBERCULOSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; PREVALENCE; REVIEW; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS CONTROL; ADULT; AIDS RELATED COMPLEX; ANTIBIOTIC RESISTANCE; CHILD; FEMALE; MALE; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DISEASE PROGRESSION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INCIDENCE; MALE; TUBERCULOSIS;

EID: 33845642079     PISSN: 00034983     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Anon. (2004). AIDS Epidemic Update. December 2004. Geneva: World Health Organization.
2. Anon. (2005). Progress on Global Access to HIV Antiretroviral Therapy. An Update on '3 by 5'. Geneva: World Health Organization.
3. Badri, M., Wilson, D. & Wood, R. (2002). Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet, 359, 2059-2064.
4. Chiba, Y. & Kurihara, T. (1979). Development of pulmonary tuberculosis with special reference to the time interval after tuberculin conversion. Bulletin of the International Union against Tuberculosis and Lung Disease, 54, 263-264.
5. Chintu, C., Bhat, G. J., Walker, A. S., Mulenga, V., Sinyinza, F., Lishimpi, K., Farrelly, L., Kaganson, N., Zumla, A., Gillespie, S. H., Nunn, A. N. & Gibb, D. M. (2004). Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet, 364, 1865-1871.
6. Churchyard, G. J., Fielding, K., Charalambous, S., Day, J. H., Corbett, E. L. Hayes, R. J., Chaisson, R. E., de Cock, K. M., Samb, B. & Grant, A. (2003). Efficacy of secondary isoniazid preventive therapy among HIV-infected southern Africans: time to change policy? AIDS, 17, 1-8.
7. Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C. & Dye, C. (2003). The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine, 163, 1009-1021.
8. Dye, C., Garnett, G. P., Sleeman, K. & Williams, B. G. (1998). Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet, 352, 1886-1891.
9. Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. (1999). Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. Journal of the American Medical Association, 282, 677-686.
10. Dye, C., Watt, C. J., Bleed, D. M., Hosseini, S. M. & Raviglione, M. C. (2005). Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. Journal of the American Medical Association, 293, 2767-2775.
11. Fitzgerald, D. W., Desvarieux, M., Severe, P., Joseph, P., Johnson, W. D. & Pape, J. W. (2000). Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet, 356, 1470-1474.
12. Frieden, T. R., Sterling, T. R., Munsiff, S. S., Watt, C. J. & Dye, C. (2003). Tuberculosis. Lancet, 362, 887-899.
13. Girardi, E., Antonucci, G., Vanacore, P., Libanore, M., Errante, I., Matteelli, A., Ippolito, G. & The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA) (2000). Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS, 14, 1985-1991.
14. Grant, A. D., Charalambous, S., Fielding, K. L., Day, J. H., Corbett, E. L., Chaisson, R. E., de Cock, K. M., Hayes, R. J. & Churchyard, G. J. (2005). Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa. A novel randomised incremental recruitment study. Journal of the American Medical Association, 293, 2719-2725.
15. Gutierrez, M. C., Brisse, S., Brosch, R., Fabre, M., Omai's, B., Marmiesse, M., Supply, P. & Vincent, V. (2005). Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis. PloS Pathogens, 1, e-Pub Aug 19.
16. Haines, A. & Sanders, D. (2005). Building capacity to attain the Millennium Development Goals. Transactions of the Royal Society of Tropical Medicine and Hygiene, 99, 721-726.
17. Hargreaves, N. J., Kadzakumanja, O., Phiri, S., Nyangulu, D. S., Salaniponi, F. M. L., Harries, A. D. & Squire, S. B. (2001). What causes smear-negative pulmonary tuberculosis in Malawi, an area of high HIV seroprevalence? International Journal of Tuberculosis and Lung Disease, 5, 113-122.
18. Harries, A. D., Hargreaves, N. J., Graham, S. M., Mwansambo, C., Kazembe, P., Broadhead, R., Maher, D. & Salaniponi, F. M. (2001a). Childhood tuberculosis in Malawi: nationwide case-finding and treatment outcomes. International Journal of Tuberculosis and Lung Disease, 6, 424-431.
19. Harries, A. D., Hargreaves, N. J., Kemp, J., Jindani, A., Enarson, D. A., Maher, D. & Salaniponi, F. M. (20016). Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet, 357, 1519-1523.
20. Harries, A. D., Zachariah, R., Bergstrom, K., Blanc, L., Salaniponi, F. M. & Elzinga, G. (2005). Human resources for control of tuberculosis and HIV-associated tuberculosis. International Journal of Tuberculosis and Lung Disease, 9, 128-137.
21. Hung, C.-C., Chen, M.-Y., Hsiao, C.-F., Hsieh, S.-M., Sheng, W.-H. & Chang, S.-C. (2003). Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS, 17, 2615-2622.
22. Korenromp, E. L., Scano, F., Williams, B. G., Dye, C. & Nunn, P. (2003). Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampicin-based treatment: an analytic review. Clinical Infectious Diseases, 37, 101-112.
23. Lambert, M.-L., Hasker, E., van Deun, A., Roberfroid, D., Boelaert, M. & van der Stuyft, P. (2003). Recurrence in tuberculosis: relapse or reinfection? Lancet Infectious Diseases, 3, 282-287.
24. Lawn, S. D., Bekker, G.-L. & Miller, R. F. (2005). Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infectious Diseases, 5, 361-373.
25. Lewis, D. K., Whitty, C. J. M., Walsh, A. L., Epino, H., van den Broek, N. R., Letsky, E. A., Munthali, C., Mukiibi, J. M. & Boeree, M. J. (2005). Treatable factors associated with severe anaemia in adults admitted to medical wards in Blantyre, Malawi, an area of high HIV prevalence. Transactions of the Royal Society of Tropical Medicine and Hygiene, 99, 561-567.
26. Lucas, S. B., de Cock, K. M., Hounnou, A., Peacock, C., Diomande, M., Honde, M., Beaumel, A., Kesters, L. & Kadio, A. (1994). Contribution of tuberculosis to slim disease in Africa. British Medical Journal, 308, 1531-1533.
27. Maher, D., van Gorkom, J. L. C., Gondrie, P. C. F. M. & Raviglione, M. (1999). Community contribution to tuberculosis care in countries with high tuberculosis prevalence: past, present and future. International Journal of Tuberculosis and Lung Disease, 3, 762-768.
28. Mermin, J., Lule, J., Ekwaru, J. P., Malamba, S., Downing, R., Ransom, R., Kaharuza, F., Culver, D., Kizito, F., Bunnell, R., Kigozi, A., Nakanjako, D., Wafula, W. & Quick, R. (2004). Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet, 364, 1428-1434.
29. Murray, C. J. L., Styblo, K. & Rouillon, A. (1990). Tuberculosis in developing countries: burden, intervention and cost. Bulletin of the International Union against Tuberculosis and Lung Disease, 65, 6-24.
30. Nunn, P., Kibuga, D., Gathua, S., Brindlc, R., Imalingat, A., Wasunna, K., Lucas, S., Gilks, C., Omwega, M., Were, J. & McAdam, K. (1991). Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet, 337, 627-630.
31. Pedro-Botet, J., Gutierrez, J., Miralles, R., Coll, J. & Rubies-Prat, J. (1992). Pulmonary tuberculosis in HIV-infected patients with normal chest radiographs. AIDS, 6, 91-93.
32. Pozniak, A. L., Miller, R. & Ormerod, L. P. (1999). The treatment of tuberculosis in HIV-infected patients. AIDS, 13, 435-445.
33. Quigley, M. A., Mwinga, A., Hosp, M., Lisse, I., Fuchs, D., Porter, J. D. H. & Godfrey-Faussett, P. (2001). Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS, 15, 215-222.
34. Raviglione, M. C. & Pio, A. (2002). Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet, 359, 775-780.
35. Raviglione, M. C., Harries, A. D., Msiska, R., Wilkinson, D. & Nunn, P. (1997). Tuberculosis and HIV: current status in Africa. AIDS, 11 (Suppl. B), S115-S123.
36. Richter, C., Ndosi, B., Mwammy, A. S. & Mbwambo, R. K. (1991). Extrapulmonary tuberculosis - a simple diagnosis? Tropical and Geographical Medicine, 43, 375-378.
37. Roberts, C. A. & Buikstra, J. E. (2003). The history of tuberculosis from earliest times to the development of drugs. In Clinical Tuberculosis, 3rd Edn, ed. Davies, P. D. O. pp. 3-20. London: Arnold.
38. Sonnenberg, P., Glynn, J. R., Fielding, K., Murray, J., Godfrey-Faussett, P. & Shearer, S. (2005). How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. Journal of Infectious Diseases, 191, 150-158.
39. Suaerez, P. G., Floyd, K., Portocarrero, J., Alarcon, E., Rapiti, E., Ramos, G., Bonilla, C., Sabogal, I., Aranda, I., Dye, C., Raviglione, M. & Espinal, M. A. (2002). Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet, 359, 1980-1989.
40. Styblo, K. & Bumgarner, J. R. (1991). Tuberculosis can be controlled with existing technologies: evidence. Tuberculosis Research Unit Progress Report, 2, 60-72.
41. Sutherland, I. (1976). Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Advances in Tuberculosis Research, 19, 1-63.
42. Toungoussova, O. S., Nizovtseva, N. I., Mariandyshev, A. O., Caugant, D. A., Sandven, P. & Bjune, G. (2004). Impact of drug-resistant Mycobacterium tuberculosis on treatment outcome of culture-positive cases of tuberculosis in the Archangel oblast, Russia, in 1999. European Journal of Clinical Microbiology and Infectious Diseases, 23, 174-179.
43. Wiktor, S. Z., Sassan-Morokro, M., Grant, A. D., Abouya, L., Karon, J. M., Maurice, C., Djomand, G., Ackah, A., Domoua, K., Kadio, A., Yapi, A., Combe, P., Tossou, O., Roels, T. H., Lackritz, E. M., Coulibaly, D., de Cock, K. M., Coulibaly, I. M. & Greenberg, A. E. (1999). Efficacy of trimefhoprim- sulphamethoxazole prophlyaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled study. Lancet, 353, 1469-1475.
44. Wilkinson, D., Squire, S. B. & Garner, P. (1998). Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. British Medical Journal, 317, 625-629.
45. Williams, B. G. & Dye, C. (2003). Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science, 301, 1535-1537.
46. World Health Organization (1994). Global Tuberculosis Programme. Framework for Effective Tuberculosis Control. Document WHO/TB/94.179. Geneva: WHO.
47. World Health Organization (1996). Guidelines for the Management of Drug-resistant Tuberculosis. Document WHO/TB/96.219 (Rev. 1). Geneva: WHO.
48. World Health Organization (1998a). Policy Statement on Preventive Therapy Against Tuberculosis in People Living with HIV. Geneva: WHO.
49. World Health Organization (1998b). Guidelines for the Control of Tuberculosis in Prisons. Document WHO/TB/98.250. Geneva: WHO.
50. World Health Organization (1999a). Preventive therapy against tuberculosis in people living with HIV. Weekly Epidemiological Record, 74, 385-400.
51. World Health Organization (1999b). Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings. Document WHO/TB/99.269. Geneva: WHO.
52. World Health Organization (2000a). Guidelines for Establishing DOTS-Plus Pilot Projects for the Management of Multi-drug Resistant Tuberculosis [MDR-TB]. Document WHO/CDS/TB/2000.279. Geneva: WHO.
53. World Health Organization (2000b). Fifty-third World Health Assembly. Stop TB Initiative, Report by the Director-General. A53/5, 5 May 2000; Resolution WHA53.1. Geneva: WHO.
54. World Health Organization (2000c). Provisional WHOIUNAIDS Secretariat Recommendations on the Use of Cotrimoxazole Prophylaxis in Adults and Children Living with HIV/AIDS in Africa. Geneva: WHO.
55. World Health Organization (2003). Treatment of Tuberculosis. Guidelines for National Programmes. Document WHO/CDS/TB 2003.313. Geneva: WHO.
56. World Health Organization (2004a). TB/HIV. A Clinical Manual, 2nd Edn. Document WHO/HTM/TB/2004.329. Geneva: WHO.
57. World Health Organization (2004b). Interim Policy on Collaborative TB/HIV Activities. Stop TB Department and Department of HIV/AIDS. Document WHO/HTM/TB/2004.330. Geneva: WHO.
58. World Health Organization (2004c). Guidelines for HIV Surveillance among Tuberculosis Patients, 2nd Edn. Document WHO/HTM/TB/2004.339. Geneva: WHO.
59. World Health Organization (2004d). Report of a 'Lessons Learnt' Workshop on the Six PROTEST Pilot Projects in Malawi, South Africa and Zambia. Document WHO/HTM/TB/2004.336. Geneva: WHO.
60. World Health Organization (2005). WHO Report 2005. Global Tuberculosis Control. Surveillance, Planning, Financing. Document WHO/HTM/TB/2005.349. Geneva: WHO.
61. World Health Organization (2006). Global Plan to Stop TB 2006-2015. Document WHO/HTM/TB/2006.35. Geneva: WHO.
62. Zachariah, R., Spielmann, M.-P., Chinji, C., Gomani, P., Arendt, V., Hargreaves, N. J., Salaniponi, F. M. L. & Harries, A. D. (2003). Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS, 17, 1053-1061.